Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924158 | 1.00 | AKT1 (0.45) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL17792462 | 1.00 | AKT1 (0.45) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL13362442 | 1.00 | AKT1 (0.45) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL9551933 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL13362435 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL5704153 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL13362538 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL5704189 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL13362441 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL13362431 | 0.96 | SYNJ2 (0.45) | AKT1CETPSYNJ2KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929567-A | With the synthetic detergent processing vanadium yellow pigment based on carbohydrate to improve the ion tolerance in alkaline medium | 赢创德固赛有限公司 | 2018-12-04 | — | — | CN | claimed |
| US-20180340071-A1 | Treatment of vanadium yellow pigments with carbohydrate-based syndets to improve ion resistance in an alkaline medium | EVONIK DEGUSSA GMBH (DE) | 2018-11-29 | — | — | US | claimed |
| EP-1130026-B1 | Composition comprising ethylhexylglucosid with a high degree of oligomerization and concentrated alkali-hydroxides | GOLDSCHMIDT AG TH (DE) | 2004-09-22 | — | — | EP | claimed |
| EP-1100329-B1 | AQUEOUS GROWTH-REGULATING COMPOSITIONS | BASF AG (DE) | 2003-11-12 | — | — | EP | claimed |
| US-6581613-B2 | Alkylpolyglucoside oligomer of given degree of oligomerization (DP), having alkyl radical of eight carbon atoms; with alkali metal hydroxide in cleaner concentrate | GOLDSCHMIDT AG (DE) | 2003-06-24 | — | — | US | claimed |
| US-6451739-B1 | ACTIVE QUATERNARY AMMONIUM COMPOUND CONCENTRATES SUCH AS MEPIQUAT OR CHLORMEQUAT AND AT LEAST ONE AUXILIARY SELECTED FROM ALKYLGLUCOSIDES, AND ALKYLSULFONATES OR ALKYLARYLSULFONATES | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | claimed |
| US-20020013253-A1 | Alkylpolyglucoside with a high degree of oligomerization | GOLDSCHMIDT AG (DE) | 2002-01-31 | — | — | US | claimed |
| EP-1130026-A2 | Alkylpolyglucosid with a high degree of oligomerization | Goldschmidt AG (DE) | 2001-09-05 | — | — | EP | claimed |
| EP-1100329-A1 | AQUEOUS GROWTH-REGULATING COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-23 | — | — | EP | claimed |
| WO-2000007445-A1 | AQUEOUS GROWTH-REGULATING COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-17 | — | — | WO | claimed |
| JP-7076503-A | — | — | None | — | — | JP | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| CN-108929567-A | With the synthetic detergent processing vanadium yellow pigment based on carbohydrate to improve the ion tolerance in alkaline medium | 赢创德固赛有限公司 | 2018-12-04 | — | — | CN | disclosed |
| US-20180340071-A1 | Treatment of vanadium yellow pigments with carbohydrate-based syndets to improve ion resistance in an alkaline medium | EVONIK DEGUSSA GMBH (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-0377349-B1 | Recombinant polypeptides of the haemorrhagical septicemia virus in fish | EUROGENTEC SA (BE) | 1994-06-08 | — | — | EP | disclosed |
| EP-0575405-A4 | — | — | 1994-03-02 | — | — | EP | disclosed |
| EP-0575405-A1 | ENDOTHELIN CONVERTING ENZYME | BERLEX LABORATORIES, INC. (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1993016674-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
| WO-1992013944-A1 | ENDOTHELIN CONVERTING ENZYME | BERLEX LABORATORIES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | AKT1 1678/4885CETP 1041/4885SYNJ2 2752/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | AKT1 1678/4885CETP 1041/4885SYNJ2 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.